Risk estimation approaches (a) Cancer risks-epidemiological approaches
In our assessment, epidemiology has already provided good evidence to support the view that the dose-response relationship for solid cancers is linear down to around 10 mGy without any detectable threshold (Japanese A-bomb survivor studies, JATB). Even if there were a threshold below this value it would make very little practical difference to risk because almost everyone would have received a dose of >10 mGy by the age of 10 from natural background radiation. It would therefore seem that there is not much justification for heavy investment by MELODI in this area with one exception, namely, a life-span study of a large cohort of individuals who sustained radiation exposures in the Chernobyl accident, as recommended by the ARCH (2010) project and approved by an independent panel set up by MELODI 1 . From a mechanistic point of view the only case made for the involvement of epidemiology is using biomarkers in association with epidemiology. This issue is addressed later in section 3 on biomarkers.
(b) Genetic risks
The 'current' estimates of genetic risks date back to 2001 and were presented in the report of the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR 2001) and the report of the United States National Academy of Sciences (the phase 2 report of the Committee on the Biological Effects of Ionizing Radiation, BEIR VII) published in 2006. Owing to the continued absence of directly usable human data on radiation-induced adverse genetic effects, estimates of risk have been obtained indirectly using mouse data on radiationinduced germ cell mutations but are expressed as predicted increases in the frequencies of genetic diseases relative to their baseline frequencies in the population. Two points must be made clear here: all such estimates are based on empirical data on the sensitivity of mouse spermatogonial stem cells to radiation-induced mutations. Although it has been assumed that the mutational sensitivity of human female germ cells (immature oocytes) and of human spermatogonial stem cells would be similar to that of mouse spermatogonial stem cells, in reality, the mutational radiosensitivity of human immature oocytes remains a complete unknown. We still lack a suitable model to assess the mutational radiosensitivity of the human female despite continuing efforts at genetic risk estimation for more than five decades! Further, although we have had considerable advances in the fields of DNA repair and human genome, MELODI does not seem to have considered projects that may attempt to produce data for risk estimation in humans which include a model for the human female as well.
Cancer mechanisms and models (a) Role of genomic instability (GI) in cancer
Since the early 1990s, an important question in mechanisms of radiation carcinogenesis has revolved around the role of genomic instability. We now know that most diagnosed cancers show multiple mutations and GI and that ionizing radiation can cause both mutations and GI, but as of now, the issue of the mechanism underpinning radiation-induced GI still remains open. The EC has supported two IPs, RISC-RAD and NOTE, at a great cost. Kadhim and colleagues (2013) have reported the main conclusions of the NOTE project according to which GI is an epigenetic phenomenon. However, a similar conclusion was reached by others as early as 2000 (e.g., Baverstock, 2000, Baverstock and Ronkko 2008, Karoti and Baverstock 2013) although Baverstock uses the term 'epigenetic' in its earlier (broader) sense, namely, 'over and above genetics' whereas in the NOTE report (Kadhim et al 2013) , the term is used to refer to 'DNA and chromatin marking'. The NOTE project 2 , however, did not fund/include studies on chromatin and DNA marking! In addition, Baverstock (2010), as a contribution to the NOTE project (Workshop in Galway, Ireland 2008), made a testable proposal for the processes underpinning GI based on a novel epigenetic regulatory process for the mammalian cell. An attempt to find a unifying mechanism for the late health effects of radiation (the primary objective of NOTE) was proposed by Baverstock and Karotki (2011).
(b) How robust are the current system of radiation protection and risk assessment?
The basic risk-based framework used in radiation protection dates back to ICRP Publication 26 in 1977, and the guidelines currently in vogue are based on ICRP 103 (2007) recommendations. Briefly, estimates of the rates of induction of cancers (based on incidence data) and of adverse hereditary effects (estimated as mentioned in section 1) were adjusted for detriment, and the detriment-adjusted risk estimates provided the basis for tissue-weighting factors and formulation of protection recommendations (see for instance, Table 15 in Sankaranarayanan and Wassom (2008)). If one looks at the recommended dose-limits, it is clear that there is no correspondence between risk estimates per se and the dose-limits and the latter have remained unchanged since 1990. This is not really unexpected because of value judgments that are incorporated in detriment estimates and, consequently, in the recommendations.
In the ICRP system, the key assumption in rate-estimates, of cancer induction, is and has always been linearity. Most of the arguments during the last 20 years or so on the validity of this assumption have revolved around experimental data which may show non-linearity, permitting the inference that the risk of cancers primarily at low doses is either over-or underestimated, (e.g., data on adaptive responses and bystander effects). The second assumption is on dose and dose-rate reduction factor (DDREF). This has been set to 2 for most cancers and to 3 for genetic effects (see section 2(d), last paragraph).
Risk estimates for cancers in the recent ICRP Recommendations are based on human incidence data and have been discussed in the UNSCEAR (2000) and BEIR VII (2006) reports in great detail. Those for adverse hereditary effects have always been arrived at indirectly using a combination of rates of induction of mutations in mouse germ cells together with the incidence data on genetic diseases in humans and population genetic theory and expressed in terms of inducible 'genetic diseases'. However, so far, there has been no evidence for radiation-induced genetic diseases in humans.
In our view, the system of radiation protection as currently used is robust and probably the best one can come up with, given the data available. A similar comment applies to assessment of cancer and genetic risks. What had been done thus far is what has been possible. However, in the current system, contributions of non-cancer effects to risk estimation are not included.
For cancer risk estimation, the lack of a single underpinning theoretical framework for the action of radiation on cells remains a major handicap. Up to 1992 radiobiology was understood on the basis of target theory and subsequent developments along similar lines. The uncovering of GI and other NTEs which did not fit within that framework undermined confidence in the necessary interpolations and extrapolations of risk within the incomplete empirical basis for risk estimation obtained from epidemiology. This problem was clearly recognized in the early 2000s with the initiation of two IPs by the EC (RISC-RAD and NOTE) designed (in the case of NOTE) to find a new paradigm to encompass classical radiobiology and NTEs. Neither of these projects provided a consensus on an underpinning framework.
(c) How can radiation protection and risk estimation be improved?
We cannot easily envision any alternative to a risk-based system of radiation protection. The question therefore is: how can the estimation of risks of cancer and genetic effects be improved? Obviously, there are no easy or unique answers. It is clear, however, in the case of cancers, that recycling old epidemiologic data either at high doses or at low doses and fitting them to doseeffect curves is not the answer. We are not aware whether any research group is involved in using genomic knowledge for cancers and examining how to use them in the context of radiation to develop mechanism-based approaches similar to what are being pursued for genetic effects by us (see later). In our view, mechanism-based approaches are more likely to provide us with the ability to predict risks.
Further, we are not aware that any research group in the European Community's program has looked at the problem of epigenetic mechanisms in radiation-induced cancers. Baverstock and Karoti (2011) proposed some potentially useful ideas on a unifying mechanism for the late health effects of radiation.
As far as genetic risks are concerned, we do not believe that there will be 'mega-mouse experiments' on radiation-induced mutations such as those carried out in Oak Ridge and elsewhere after World War II, in the 21st century. There are at least three reasons for this: first, the conceptual framework of genetic risk estimation has changed to reflect new realities. From basic studies in human genetics and mechanisms of induction of radiation damage in cells and the molecular nature of radiation-induced genetic damage, we now have a clearer idea of how adverse genetic effects in humans may be manifest. Second, advances in genome research, DNA repair and radiation mutagenesis are providing us with unprecedented opportunities to apply the knowledge that has emerged from these studies to estimate risks directly on the basis of human data without using indirect approaches as has been the case thus far. Finally, no institution/country can now afford to spend millions of dollars or euros on acquiring additional mutation rate data from experimental systems even if new mutation systems can be defined! We do not, of course, exclude the possibility that animal experiments may be needed to test specific hypotheses developed on the basis of human observations. Directly relevant new human radiation data on adverse genetic effects are unlikely to be generated in the foreseeable future. Computational modeling approaches such as the ones discussed by Sankaranarayanan and Wassom (2005) and Sankaranarayanan and Nikjoo (2011) which initiated the use of genomic knowledge and mechanisms of induction of mutations represent one of the best options. We are now concerned about what baseline one would use for risk estimation here, given the observations of enormous amount of structural variability in the human genome and that there is no longer a single reference human genome sequence! We are not aware of any major efforts being funded in the genetic risk area by the MELODI/DoReMi! In the absence of human data especially at low doses below 100 mSv, it seems to us that the only way to proceed is by formulation of mechanistic models from initial damage to induction of biological lesions of importance to estimate genetic and cancer risks. Advances in knowledge of the human genome in health and disease and DNA repair processes now have presented us with unprecedented opportunities to construct such models, which will allow estimation of risk from exposures to low dose radiation. Despite the fact that DNA repair (both experiments and mathematical models) is central to a mechanistic description of damage leading to cancer and genetic effects from exposure to IR, no efforts in this area have been The paper by Salomaa et al (2013) argues for a better understanding of cancer mechanisms because it can help to arrive at better risk estimates at doses <100 mSv and <10 mSv. It is argued that the uncertainty in epidemiology is such that it "restricts the risk estimates to those irradiated individuals receiving a high to moderate dose". However, what we know from the JATB studies (which indicate linearity down to <100 mSv for solid cancers) and the absence of a dose-rate dependence from other lower dose rate studies (i.e. Techa River (IAEA publications; Aarkrog et al 2000)) leads to a reasonable inference of linearity down to low doses. All these strongly support the view that we may not be in error in adopting a DDREF = 1. This issue was addressed in some detail in the EC funded ARCH project (2010). Thus when the paper by Salomaa et al states: "The Euratom Network of Excellence DoReMi has clearly identified the resolution of the shape of the dose response curve from high to low doses as a key research priority.", it is difficult to understand what exactly they believe is missing. Whether the Techa River data will necessitate a revision of DDREF and consequently risk coefficients for cancer at low doses remains to be seen.
Biomarkers
The SRA places a very heavy reliance on the need for biomarkers for the anticipated diseases induced by radiation ("In order to relate these reactions (caused by radiation in cells) to irreversible metabolic or to irreversible pathological reactions it is necessary to identify specific biomarkers linked to radiation exposure as well as to normal, pre-pathological and pathological states."). Yet it is acknowledged (Salomaa et al 2013) that there are none at present and considerable scepticism was expressed in a poll of those attending the meeting in Helsinki, although ∼65% clearly thought that it would be good if a biomarker could be found. The most fruitful place to look for a biomarker for radiation-induced cancer is the thyroids of children (the younger the better) contracting childhood thyroid cancer after the Chernobyl accident (Baverstock 2011 , UNSCAER 2000 . Extensive studies of this population have yielded zero results for molecular biomarkers and some weak and inconsistent evidence of associations with gene expression markers as confirmed by the presentation of Zitzelberger (2012) at the Helsinki meeting.
The Addendum to the Technical Report of the ARCH Project (2010) makes the case that exposure to radiation will not leave markers in the form of molecular damage. Process markers may be found but these require either proteomic or gene expression analysis on the tissue concerned (i.e., will require biopsy) and should preferably be assessed shortly after the exposure. In a review paper (Pernot 2012) it is proposed that GWAS might come to the rescue. However, attempts to link SNPs to common diseases (as opposed to a few rare conditions) have been markedly unsuccessful. In general, SNPs in exons seem to have very little effect on phenotype (not unexpected since they likely would have to affect the few active site amino acids in the protein), leaving just intronic and extragenic SNPs of unknown biological significance.
The paper by Neta et al (2011) has looked for associations between papillary thyroid cancer and SNPs on genes dealing with DNA repair and other activities and the results were negative. The paper by Kraemer et al (2011) investigates the role of small RNAs in post-translational regulation. The conceptual framework underpinning this paper provides no mechanistic basis for post-translational regulation. It seems that if the transcription of some small RNAs is blocked in irradiated cells (2.5 Gy), (but does not appear relevant to radiological protection and the low dose problem), recovery is impaired.
The paper by Raj and Boufler (2012) Reply to 'State of the art in research into the risk of low dose radiation exposure'
Dear Sir
We are grateful to Drs Nikjoo and Sankaranarayanan for their constructive comments and thoughts about the past and future strategy of low dose research in Europe. In their letter the authors touch three main issues: (1) risk estimation approaches, (2) cancer mechanisms and models and (3) biomarkers. Following a discussion among the authors of our memorandum we decided not to answer their comments point by point, but rather give a general response that, we hope, explains the philosophy behind the adopted strategy of European research on effects and risks of low dose radiation. It is the strong belief of the European MELODI initiative that progress in the field of low dose risk research can best be achieved in a multidisciplinary approach using the huge advances made during recent years in various scientific disciplines outside the classical radiation research domain. The focus on isolated individual research projects is considered unrewarding. Given the complexity of the underlying scientific questions to be resolved, a common vision on the priorities of research is needed at an international level. As a consequence, a long-term vision and continuity of funding is needed. MELODI follows this approach by developing its strategic research agenda further with all stakeholders who are willing to contribute-the MELODI workshops are a forum for this development; they are open to anyone. Research activities, which are based on recommendations by MELODI, are typically funded both by public money available at EU and at a national level.
Consistent with this basic belief of MELODI, the 172 participants of the 4th MELODI workshop discussed the status of our current knowledge in the various areas of low dose risk in an open and transparent process and identified key areas for future work. The findings are in agreement with the recommendations of the 2013 UNSCEAR 'children' report, which "identified the following areas for future research: development of databases on radiation doses for children who can be tracked in the long term; and evaluation of effects following whole and partial irradiation of juvenile organs. Studies at the molecular, cellular, tissue and juvenile animal level are potentially informative" (UNSCEAR 2013). The research areas addressed by Nikjoo and Sankaranarayanan in their comments are not inconsistent with this wider research agenda.
As for risk assessment, both European and US scientists are in favour of bringing together epidemiology and mechanistic studies. In Europe, the efforts are focused on molecular epidemiology whereas the US clearly favour development of biologically-based risk models (NCRP 2012, Preston et al 2013). Both approaches require mechanistic studies and consideration of biomarkers. This example clearly demonstrates the need for an SRA and a roadmap. Even with the fast evolution of molecular biology, the work will require long-term engagement of the scientific community and nobody can predict with certainty what the final outcome will be. There is no question that epidemiological studies and the follow-up of the most suitable cohorts applying improved dosimetry and other means to reduce uncertainties have an important role to play in this development. The potential role of non-cancer effects in the system of radiological protection continues to be a key question. This has been highlighted in the European program and, in fact, NOTE was the first EU project to address potential mechanisms for such tissue reactions.
Europe is now leading in this research area and in low dose risk research overall. Based on the experience of the cooperation in MELODI, we are confident that the way pursued to prioritize and organize research is well targeted to achieve reliable results and to answer the open questions in the area of low dose risk research. The selection of parameter values in studies of environmental radiological impacts
References

Dear Sir
We read with great interest the paper of Thorne (2013) because of the constructive criticism the author provided in relation to the treatment of uncertainty in the ERICA Tool (Brown et al 2008)-a software package that we developed for the tiered assessment of radiological risk to plants and animals. Thorne (2013) notes that the treatment of uncertainty in the ERICA Tool 'is not likely to be valid in the assessment contexts in which it will typically be employed'. We reply to this criticism in this letter. The ERICA Tool (at Tier 2) has uncertainty factors that are intended to provide an approximation of the 95th or 99th percentile risk quotient (RQ 3 ). The 95th and 99th percentiles of the RQ are estimated by multiplying the expected value of the RQ by an uncertainty factor (UF). The uncertainty factor is defined as the ratio between the 95th, 99th or any other percentile (above the expected value) and the expected value of the probability distribution of the dose rate (and RQ). To estimate the UF values it is assumed that the dose rate and the RQ follow exponential distributions with arithmetic means equal to the estimated expected values. In this case the UFs corresponding to the 95th and 99th percentiles are equal to 3 and 5 respectively. Thorne (2013) Thorne (2013) raises an important issue that the exponential distributions applied in the ERICA Tool to characterise uncertainties may not be suitable because models such as those used in the Tool, based primarily on concentration ratios (CRs; radionuclide activity concentrations in organisms relative to those in soil or water) and environmental measurements, tend to exhibit lognormal distributions. Hence, uncertainties on derived dose-rates and risk quotients, RQs, might also be expected to follow lognormal distributions. Although this contention appears on first reading sensible and reasonable, we feel it necessary to quickly explain the original rationale behind our selecting an exponential distribution. In the ERICA Tool (at Tier 2) we use arithmetic mean values for all variables (parameters) involved in the calculations (concentrations in environmental media, distribution coefficient (K d ), CR, dose conversion coefficient (DCCs), etc). Hence, we obtain mean (expected) values of the RQs (referred to as the 'expected' RQ in the ERICA Tool). These deterministically calculated RQs do not include information on the variation (uncertainty). Knowing only expected values, from the Maximum Entropy Method (Harr 1987) , we could only assume that RQs follow an exponential distribution; additional information would be required to assume any other distribution. For example, assuming a lognormal distribution would require that the standard deviation is known. Nonetheless, we acknowledge that an appropriate standard deviation to apply might be estimated from published literature or through analyses of how uncertainty factors change as a function of standard deviation, thus giving the option of selecting conservative estimates of UF as proposed by Thorne (2013) .
A more subtle argument against the perfunctory application of the distributions suggested by Thorne (2013) lies in the consideration that we cannot be certain that RQs are best characterised by lognormal distributions. If several variables that follow lognormal distributions are multiplied the result will be also a lognormal distribution. But if one or more of the input variables does not fit well to a lognormal distribution and/or several components (such as internal and external dose) are being summed then the result may also diverge from a lognormal distribution. The ERICA Tool provides estimates of the UFs under certain assumptions. Furthermore, in recognising that the UFs are case-specific, the user is given the possibility of entering their own value of UF. On balance, we acknowledge that assumptions and limitations of the default UFs were not well described within the ERICA Tool documentation.
A close examination of the article by Thorne (2013) shows that there are errors in the calculation of UFs (by Thorne). This becomes apparent by comparing figure 3 in Thorne's paper with figure 1 here, which shows the correct relationship of uncertainty factors and natural logarithm of GSDs for lognormal distributions. This has substantial implications for the selection of appropriate conservative uncertainty factors based on the approach proposed by Thorne (2013) , i.e. using uncertainty factors in the range 7 to 28, as representative of the maximum values for the 95th and 99th percentiles respectively. However, as seen from figure 2, values of 7 and 28 represent maximum UFs for 97.5 and 99.5 percentiles respectively and they correspond to GSD values which can be reasonably considered as extreme, as Thorne (2013) noted "For well-characterised environmental variables the value of sigma is typically 2 to 3 . . . .". It seems that the suggested values are therefore based on results for the wrong percentiles and scale.
In order to further elaborate on the selection of appropriate uncertainty factors, we provide (table 1) . These values are much lower than the values presented in Thorne (2013) . In the ERICA Tool, the UFs correspond to the 95th and 99th percentiles with default values of 3 and 5 respectively. These are similar to the values obtained for a lognormal distribution with GSD 3 for the 95th and 97.5th percentiles, respectively (table 1). The suggested UF value of 5 for the 99th percentile in the ERICA Tool is therefore underestimated (from table 1 a value of 7 would be more appropriate), although not to the extent suggested by Thorne. We would like to conclude by acknowledging that the article of Thorne (2013) , whilst in error, has demonstrated the need to review the UFs in Tier 2 of the ERICA Tool, a task we plan to perform in the near future. 
Yours sincerely,
Rodolfo
Reply to 'The selection of parameter values in studies of environmental radiological impacts'
Dear Sir
In their letter, Avila et al make some important and relevant comments, and identify significant errors in Thorne (2013) . However, there are a number of points on which some further remarks are appropriate. First, there is a matter of nomenclature. In the caption to figure 3 of Thorne (2013) σ is equated with the geometric standard deviation of a lognormal distribution. In fact, σ is the standard deviation of the natural logarithm of the variable characterising the distribution. The geometric standard deviation is e σ . Thus, figure 1 in Avila et al's letter correctly shows the x-axis as Ln(GSD). This is correctly labelled σ in figure 3 of Thorne (2013), but incorrectly described in the figure caption as the geometric standard deviation.
On a more substantial point, Avila et al comment that because they use arithmetic mean values for all variables in the calculation of Risk Quotients (RQs) they calculate mean (expected) values for those RQs and that these mean RQ values do not include information on the uncertainty. They then argue that the only thing that they know is the mean value, so the Maximum Entropy Method requires that they use an exponential distribution. Where they speak of the mean (expected) value of an RQ, they presumably intend the arithmetic mean, since this is the quantity required in the exponential probability distribution, see equation (4) of Thorne (2013) .
However, the arithmetic mean values for the individual variables are computed from empirical observations. Therefore, much more is known than the arithmetic mean values for those variables, e.g. higher moments of their distributions can be computed. Furthermore, application of the Maximum Entropy Method results in an exponential distribution only if the mean is known for a variable that lies in the range [0, ∞]. This means that, if there are physical constraints that limit the maximum value of the variable, then application of the Maximum Entropy Method does not result in an exponential probability distribution. Indeed, the appropriate distribution is necessarily bounded at the maximum physically achievable value of the variable. It is also important to recognise that using the arithmetic mean values for input variables taken from probability density functions (pdfs) for those variables does not, in general, result in the arithmetic mean for the output variable that would be obtained by propagating the pdfs for the input variables through the calculation. This is readily illustrated in the following example. Let x and y be independent variables each uniformly distributed on the interval [0, 1]. Thus, the arithmetic mean of each of these variables is 0.5. Let an output variable z be defined as z = Note that this issue arises even if only one variable is considered. Thus, if z = x p , the two approaches give 0.5 p and 1/(p + 1), respectively. Only if the output from a model is linearly dependent on the inputs (p = q = 1 in the above) is it legitimate to take arithmetic means of the input quantities to compute the arithmetic mean of an output quantity.
Overall, if there is enough information to compute the arithmetic mean value of a quantity, there is generally sufficient information to say something about the uncertainty in that quantity. Even if only a single measured value is available, there will usually be some background information available that constrains the plausible range of the variable. If no measured values are available, then there is little basis for computing a RQ. Thus, in practice, it will almost never be legitimate to use an exponential distribution to represent parametric uncertainty in environmental variables. Furthermore, even if it were legitimate, the value of the output variable obtained from a deterministic calculation using the arithmetic mean values of the input variables would not, in general, be the arithmetic mean value that should be inserted into that exponential formulation. This latter point does not affect the estimate of the uncertainty factor (which does not depend on the value of the mean of an exponential distribution), but does affect the RQ estimate to which that uncertainty factor is applied.
Finally, consideration has to be given to the issue of the confidence levels to be attached to the curves shown in figure 3 of Thorne (2013) and reproduced in figure 1 of Avila et al. Thorne (2013) claims that these are 95th and 99th percentiles, whereas Avila et al have determined that they are 97.5th and 99.5th percentiles. This difference arises because table 1 of Thorne (2013) relates cumulative probabilities (y) to values of y. The quantiles of the standard normal distribution are commonly denoted as z p . A normal random variable x will exceed μ + σ z p with probability 1 − p, and will lie outside the interval μ ± σ z p with probability 2(1 − p). In particular, the quantile z 0.975 is 1.96; therefore a normal random variable will lie outside the interval μ ± 1.96σ in 5% of cases. Table 1 of Thorne (2013) gives the 95th percentile at 1.96σ above the mean. From the above, it will be seen that the proper interpretation of this is that a random normal variable will lie outside the range μ ± 1.96σ in 5% of cases. However, the random normal variable will lie above μ + 1.96σ in only 2.5% of cases. Thus, as uncertainty factors are used only to establish upper bounds on RQ values rather than both upper and lower bounds, Avila et al are correct in assigning increased percentiles to these curves.
In summary, Avila et al have made a valuable contribution to the discussion on an appropriate choice of uncertainty factors for environmental modelling. It is hoped that this response to their letter will help to further clarify the issues and contribute to progress in this area.
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Yours sincerely,
M C Thorne
Mike Thorne and Associates Ltd, Durham, UK
Radiation dosimetry assessment of routine CT scanning protocols used in Western Australia
The recent paper by Moorin et al [1] described the dosimetry assessment of CT scanning protocols used in Western Australia. The paper made some inaccurate assertions concerning Australian DRLs that need to be addressed. In particular Moorin et al state that 'while Australia has developed some clinical guidelines, it has not implemented diagnostic reference levels. . . ' and additionally that 'The only study. . . to assess CT utilisation and dosimetry in Australia was a survey in 1996. . . '. The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) launched a national web-based survey of common CT protocols in August 2011. Data collected during 2011 were used to calculate the first Australian National Diagnostic Reference Levels for Multi Detector Computed Tomography, which were published on the ARPANSA website in June 2012 [2, 3] . The DRLs were established with a large collaborator stakeholder group including the Royal Australian and New Zealand College of Radiologists (RANZCR), the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM), the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) and the Australian Institute of Radiography (AIR). Before publication the DRLs were extensively advertised throughout the Australian radiological community. The ARPANSA survey, or 'Australian National Diagnostic Reference Level Service' as it has recently been rebranded, is currently in its third year of operation. It should be noted that it is a mandatory regulatory requirement of each State and Territory that every radiology facility complies with RPS 14, the ARPANSA Code of Practice for Radiation Protection in the Medical Applications of Ionizing Radiation. Section 3.1.8(a) of the Code requires that radiation doses administered to a patient for diagnostic purposes are periodically compared with established DRLs [4] . The Service is available to all radiology practices Australia-wide and all participation is voluntary. Practices can complete an unlimited number of individual surveys for specific protocols, defined by choice of body habitus, acquisition protocol and age group. Each survey requires the Dose Length Product (DLP), volume Computed Tomography Dose Index (CTDIvol), patient weight, patient age and patient sex for a minimum set of ten patients, although 20 are preferably requested. On submission of a compliant survey a practice report is automatically generated that compares the Practice Reference Level (the median of the DLP and CTDIvol values), with the Australian National DRL for that protocol and age group.
The Australian National DRLs were calculated by rounding the 75th percentile of the spread of PRL values for each habitus protocol and age group. The median was chosen to calculate the PRL values as it better compensates for outliers than the mean as there were no weight restrictions in the patient sample. The average patient weight recorded in 2011 was 76 ± 17 kg, but no comparison can be made with the data of Moorin et al as they do not define their 'standard adult patients' in any way. Table 1 shows the total surveys submitted and the total number of practices contributing these surveys for 2011 and 2012 nationally and specifically from Western Australia. Figure 1 shows the 75th percentile as reported by Moorin et al, compared with the Australian National DRL values published in 2012. Also shown is the 75th percentile of the Australian survey data submitted during 2011 and 2012 nationally and specifically from Western Australia.
The 75th percentile DLP values reported by Moorin et al are significantly higher than those collected from the Australian National Diagnostic Reference Level Service, even when considering only Western Australian data. A difference in data collection methodology was that Moorin et al requested a specific clinical indication for the sampled body habitus, while the ARPANSA survey simply requested body habitus only. The Australian DRL values were calculated from a larger sample of practices which may indicate that the practices sampled by Moorin et al were biased toward the high end of the dose distribution and as such not indicative of true Western Australian practice. As participation in the ARPANSA National Diagnostic Reference Level Service is voluntary it may also be argued that early adopters of the service represent good practice and as such would skew the data to be lower than the actual National or State average. However, data submitted during 2012, the second year of operation, produced Reply to 'Radiation dosimetry assessment of routine CT scanning protocols used in Western Australia'
Dear Sir
We welcome the opportunity to respond to comments by Wallace et al on our paper 'Radiation dosimetry assessment of routine CT scanning protocols used in Western Australia' [1] . We acknowledge that the publication of results of the first ARPANSA DRL survey on the ARPANSA website did predate the submission of our manuscript to the journal by three months (June to September). This should have been reported in our paper and informed the discussion; however, at the time of submission no peer-reviewed scientific publication was identified containing this information.
We believe the significant methodological differences between our study and the Australian National DRL survey is the explanation for the variation in doses reported and highlighted by Wallace et al. The largest contributor to the differences in dose values reported by our study and the Australian National DRLs is the approach to defining protocols and the incorporation of multiple sequences (phases). Our method of data collection was based upon clinical scenario (for example, three distinct chest scenarios each having a different dosimetry profile due to distinct differences in their technical parameters) in the same manner as undertaken by the UK dose survey (a validated international survey tool) [2] . In comparison, the Australian National DRL survey focuses on anatomically based CT scanning (i.e. CT chest with no specific clinical indication provided). Inherent in the use of clinically based protocols is the idea of a scenario that incorporates multiple sequences when undertaken routinely. In our study five of the seven clinical scenarios included multiple sequences for the reported standard protocol. We subsequently summed the dose values for these sequences to create a 'Protocol Dose Length Product (DLP)' and 'Protocol Effective Dose'. While the Australian National DRL survey does request information on the number of sequences/phases it is unclear how multiple phases were accounted for by the ARPANSA survey. Anecdotal evidence from a WA provider, who has participated in the ARPANSA survey, suggests confusion as to what was required by ARPANSA with regard to multiple phases and examination setting.
This variation between 'patient oriented' and 'anatomical area oriented' assessments of dose values represents a significant disparity between our two methodologies and subsequently impacts the comparison of our results with those of ARPANSA. However, this issue is broader than any single DRL methodology as CT literature is endemic with research applying dose values to broadly labelled anatomical areas, often without qualification of the actual CT protocol used or clinical scenario precipitating the scan. In a study currently under review, which used data collected directly from Picture Archiving and Communication System data, we have found that doses from discrete protocols within an anatomical area can vary substantially. The main concern with a DRL approach lacking in clinical specificity is the risk of reduction in clinical relevance. Hopefully this can be considered in future DRL surveys to disambiguate these areas, or perhaps create separate DRLs for clinical setting (hospitals and private practice, for example).
Our data collection methodology was a combination of self-complete surveys (as per the UK dose survey) [2] followed by the addition of in-depth interviews with participants regarding information provided in their completed survey. In most cases this involved confirmation and clarification of data provided by means of additional data collection from the respondent directly to the researcher. The interviews were in addition to the UK dose survey instrument methodology, and were undertaken to improve data quality and validity. We felt this approach ensured more accurate representation of each provider's typical scanning protocol, generated more rigorous data and removed some of the issues inherent with selfreport surveys. Unfortunately this additional data collection activity also reduced our sample size since only those respondents who agreed to undergo interview (five out of eight providers who participated in the survey phase) were included in the paper.
Wallace et al observed that our study did not collect patient weight. Our collection of protocol data and dose outputs (e.g. DLP) followed the UK DRL survey methodology [2] , which asks for data pertaining to routine protocols undertaken on average sized adult patients excluding those who were excessively large or excessively small (thus removing patients for whom the routine CT scanning protocol is likely to be adjusted). The effective dose data were then generated via the ImPACT Dose Calculator, which uses an 'average' adult phantom based Monte Carlo modelling [3] . While ARPANSA has collected patient weight in its survey methodology, it is unclear what role this information has played in the calculation of Australian National DRLs.
As Wallace et al noted, the sample size of our study was substantially smaller than the national DRL survey. We agree with this comment and noted the limitation of our study's sample size on page 309, "One limitation of our study is that it included only a limited sample of CT providers in WA and therefore may not be representative of all providers." As with several international initiatives relying on voluntary participation to capture data on which to build DRLs, the response fraction in our study was low (approximately 20%) and this compares favourably with the 2012 ARPANSA survey (23%) and other international studies (25% in the 2003 UK dose survey) [2] . Our extrapolation of dose variation to population values (figure 4) was not performed to represent the actual impact of WA or national scanning practices but to demonstrate the population level impact of observed variation (i.e. low, median and higher) dose scenarios. In this purpose we are in alignment with ARPANSA's goal to place responsible downward pressure on medical radiation dose values.
Wallace et al commented on the voluntary nature of the Australian National DRL survey, which carries a risk of self-selection for participation. We agree, and our survey, like all voluntary self-report surveys, suffers from this limitation. We disagree, however, with the argument that the ARPANSA 2011 survey was not subject to a self-selection bias on the basis of the 2012 survey producing similar results. It seems entirely plausible that new 2012 participants were of a similar mentality and practice approach to the 2011 cohort. It is also plausible that those practices who generate substantially higher doses would choose not to participate to avoid any scrutiny or comparison with lower dose practices. Setting aside sample and specificity differences between our methods, Wallace et al correctly identify that the practices our study sampled could have differed substantially from the WA practices participating in the Australian National DRL surveys in dose value (with a bias towards higher doses from our participating practices).
We agree with Wallace et al that the disparity of our results from the Australian DRLs, difficulties in methodological comparisons aside, combined with the apparent reduction in participation in national dose survey activities in Western Australia that is against the increasing participation trend observed nationally, suggests a need for review and dose optimisation in WA. The Australian DRLs represent a positive step towards greater dose consciousness and awareness in the radiological community. However, as long as the Australian National DRL survey remains voluntary there will always be uncertainty around Australian CT doses.
On the definition of the ICRP reference 'Brown Seaweed' implemented in the ERICA software
The evaluation of the radiological burden on the environment due to the release of radioactive contaminants having an anthropogenic origin is a challenging issue. To this end, a number of models and software tools have been proposed, based on simplified models of the geometry, habits and bioaccumulation characteristics of non-human biota.
The International Commission on Radiological Protection, in its Publication 108 (ICRP 2008), defined the Reference Animals and Plants recommended to be employed in environmental protection. The model adopted an ellipsoidal shape for all organisms.
In the subset of the reference plants living in aquatic environments, 'Brown Seaweed' was proposed as the Reference Seaweed in section 2.5.12, its size and weight being defined in section 4.5.12 (ellipsoid of 50 × 50 × 0.5 cm axes, mass 0.652 kg) and reported in table 4.2.
In Publication 108, the ICRP also adopted the analytical model for the calculation of the dose conversion coefficients (DCCs) previously developed by Ulanovsky and Pröhl (2006a, 2006b) . However, that model assumed an ellipsoidal shape of brown seaweed with axes of 50 × 0.5 × 0.5 cm and a mass of 6.54 × 10 −3 kg (see table 5 of Ulanovsky and Pröhl (2006a, 2006b)).
When using the ERICA software tool (Brown et al 2008) , in which the analytical model of Ulanovsky and Pröhl was implemented, we identified the discrepancy between the size of the Reference ERICA organism 'Marine Macroalgae', 50 × 0.5 × 0.5 cm, which should be the same as the 'ICRP Brown Seaweed'.
As a consequence, a difference in the DCC values arises between the DCC value found by Ulanovsky and Pröhl (2006a, 2006b ) and the relative DCCs published in Annex C of ICRP Publication 108. Such differences depend upon the radionuclide emission spectrum, if the absorbed fraction of each emitted radiation is significantly different in the two geometries.
In table 1 we compare some of the DCC values published by Ulanovsky and Pröhl (2006a, 2006b), for the same geometry referred in the ERICA tool, with the corresponding data from In the same table, we also report the DCC values calculated by means of an alternative analytical approach for the determination of alpha, electron and photon absorbed fractions, previously published (Amato et al 2009a (Amato et al , 2009b (Amato et al , 2011 (Amato et al , 2013 , together with the relative differences.
The agreement between the differences found with our model for the two geometries and the ones derived from the comparison between Ulanovsky and Pröhl (2006a, 2006b) and ICRP Pubblication 108 data demonstrates that these last differences are attributable to the different value of the second axis of the ellipsoid.
In more detail, DCC values for 14 C are the same because the low-energy beta electrons (E = 49.5 keV) are almost totally absorbed in the thinner model; also the alpha particles of 241 Am and 238 U, carrying most of the energy emitted per disintegration, are totally absorbed in both geometries.
Differences arise for 90 Sr, since its daughter 90 Y, considered in the calculation, is a highenergy pure beta emitter (Ē = 934 keV) and its absorbed fraction is far from saturation in the first model. The same reason leads to the lower difference found in the medium-energy beta emitter 137 Cs, whereas the well-known high-energy de-excitation peak at 662 keV of 137 Ba gives a negligible contribution in both cases.
As a concluding remark, we would like to comment on the definition of this reference organism. The ICRP Brown Seaweed is defined as a Cyclosporean brown intertidal seaweed (section 2.5.12). It is to be intended as a single organism (section 4.5), since only Crab eggs and Grass meristem are treated as a collective mass. Typical examples of brown seaweeds are kelps or bladder wrack (Fucus vesiculosus). The morphology and size of these marine organisms may vary considerably but, in general, each seaweed typically forms extended beds of thickness 1 cm or more. Therefore, in our opinion, the sheet definition reported in ICRP Publication 108 could be considered more appropriate. Amato 
